HRMY
Harmony Biosciences Holdings Inc (HRMY)
Healthcare • NASDAQ • $34.45+0.85%
- Symbol
- HRMY
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $34.45
- Daily Change
- +0.85%
- Market Cap
- $1.93B
- Trailing P/E
- 13.42
- Forward P/E
- 5.96
- 52W High
- $40.87
- 52W Low
- $25.52
- Analyst Target
- $44.36
- Dividend Yield
- N/A
- Beta
- 0.97
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and othe…
Company websiteResearch HRMY on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.